See more : Ashler et Manson SA (MLAEM.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Asia Green Biotechnology Corp. (ASIA.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Asia Green Biotechnology Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- TSUKADA GLOBAL HOLDINGS Inc. (2418.T) Income Statement Analysis – Financial Results
- PWP Forward Acquisition Corp. I (FRW) Income Statement Analysis – Financial Results
- Redcastle Resources Limited (RC1.AX) Income Statement Analysis – Financial Results
- Fiducial Office Solutions (SACI.PA) Income Statement Analysis – Financial Results
- Mangels Industrial S.A. (MGEL4.SA) Income Statement Analysis – Financial Results
Asia Green Biotechnology Corp. (ASIA.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
About Asia Green Biotechnology Corp.
Asia Green Biotechnology Corp., an early stage international bio-technology company, focuses on the development, evaluation, testing, application, and supply of products derived from proprietary organic hybridization technology in Asia. The company focuses on planting, growing, and harvesting new and valuable strains of hemp and related crops. It has an agreement with Pathway Rx Inc. and PNW Biosciences Inc. for the clinical development and commercialization of the cannabis sativa varieties for prevention and treatment of COVID-19 and other infectious diseases. The company was formerly known as Asia Cannabis Corp. and changed its name to Asia Green Biotechnology Corp. in April 2020. Asia Green Biotechnology Corp. was incorporated in 2017 and is based in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 40.77K | 158.67K | 116.15K | 22.76K | 0.00 |
| General & Administrative | 144.74K | 117.00K | 267.85K | 346.39K | 598.05K | 911.35K |
| Selling & Marketing | 0.00 | 0.00 | 31.80K | 35.30K | 16.75K | 5.25K |
| SG&A | 144.74K | 117.00K | 299.65K | 381.69K | 614.80K | 916.60K |
| Other Expenses | 0.00 | 21.43K | 64.92K | 55.00K | 89.63K | -4.98K |
| Operating Expenses | 144.74K | 179.21K | 523.24K | 552.83K | 727.18K | 916.60K |
| Cost & Expenses | 144.74K | 179.21K | 523.24K | 552.83K | 727.18K | 916.60K |
| Interest Income | 30.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 19.11K | 1.28K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 236.56K | 206.30K | 171.86K | -4.98K |
| EBITDA | 23.16K | 0.00 | -523.24K | -552.83K | -687.18K | -916.60K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -144.74K | -179.21K | -523.24K | -552.83K | -687.18K | -916.60K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -76.44K | -2.00K | -30.26K | -22.50K | -92.39K | -4.98K |
| Income Before Tax | -221.17K | -198.32K | -524.52K | -552.83K | -767.18K | -921.58K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -162.02 | 1.28K | -552.83 | 40.00K | 4.98K |
| Net Income | -221.17K | -198.32K | -525.80K | -552.83K | -807.18K | -921.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 |
| EPS Diluted | -0.01 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 |
| Weighted Avg Shares Out | 22.12M | 36.11M | 34.00M | 28.12M | 23.54M | 36.25M |
| Weighted Avg Shares Out (Dil) | 36.25M | 36.11M | 34.00M | 28.12M | 23.54M | 36.25M |
Source: https://incomestatements.info
Category: Stock Reports